517 related articles for article (PubMed ID: 18287273)
1. Recommendations on the use of 18F-FDG PET in oncology.
Fletcher JW; Djulbegovic B; Soares HP; Siegel BA; Lowe VJ; Lyman GH; Coleman RE; Wahl R; Paschold JC; Avril N; Einhorn LH; Suh WW; Samson D; Delbeke D; Gorman M; Shields AF
J Nucl Med; 2008 Mar; 49(3):480-508. PubMed ID: 18287273
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
Reske SN; Kotzerke J
Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
5. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
[TBL] [Abstract][Full Text] [Related]
6. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
[TBL] [Abstract][Full Text] [Related]
7. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
8. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
[TBL] [Abstract][Full Text] [Related]
10. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
12. FDG PET/CT in cancer: comparison of actual use with literature-based recommendations.
Petersen H; Holdgaard PC; Madsen PH; Knudsen LM; Gad D; Gravergaard AE; Rohde M; Godballe C; Engelmann BE; Bech K; Teilmann-Jørgensen D; Mogensen O; Karstoft J; Johansen J; Christensen JB; Johansen A; Høilund-Carlsen PF;
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):695-706. PubMed ID: 26519292
[TBL] [Abstract][Full Text] [Related]
13. A brief review of Japanese guidelines for the clinical use of (18)F-FDG-PET/MRI 2012 (Ver 1.0).
Kaneta T
Ann Nucl Med; 2013 May; 27(4):309-13. PubMed ID: 23508379
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of head and neck cancer with (18)F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch H; Kogler D; Wieser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 24770459
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
16. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
17. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
Menda Y; Graham MM
Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma.
Kim SY; Kim JS; Yi JS; Lee JH; Choi SH; Nam SY; Cho KJ; Lee SW; Kim SB; Roh JL
Ann Surg Oncol; 2011 Sep; 18(9):2579-84. PubMed ID: 21409485
[TBL] [Abstract][Full Text] [Related]
19. Standards for PET image acquisition and quantitative data analysis.
Boellaard R
J Nucl Med; 2009 May; 50 Suppl 1():11S-20S. PubMed ID: 19380405
[TBL] [Abstract][Full Text] [Related]
20. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
